Research programme: anti-IL2 receptor antibody - Amgen

Drug Profile

Research programme: anti-IL2 receptor antibody - Amgen

Alternative Names: MT-204

Latest Information Update: 09 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Micromet Inc
  • Developer Amgen
  • Class Antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 18 Mar 2008 Preclinical development is ongoing
  • 20 Mar 2007 Micromet is looking for outlicensing opportunities with respect to MT 204 (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top